A landmark study has successfully generated the world's first functional organoids of the human meibomian gland, the essential structure within the eyelid that prevents dry eye. Published in Protein & Cell by a collaborative team led by Professor Bing Zhao from Nanchang University​ and Chief Physician Jiaxu Hong from Fudan University Eye & ENT Hospital, this research establishes a pioneering model to accelerate drug discovery and advance regenerative therapies for a condition affecting hundreds of millions worldwide.

The core challenge in treating meibomian gland dysfunction, the leading cause of evaporative dry eye, has been the inability to repair the degenerated glandular tissue. This work overcomes a major historical barrier by creating the first faithful human model: self-organizing three-dimensional "mini-glands" in the laboratory. These organoids accurately replicate the gland's architecture, contain the correct cell types, and critically perform their key function of producing the characteristic oils that stabilize tears. Lipidomic analysis confirmed that their secretory output closely resembles that of native tissue, validating the model's biological relevance.

The utility of this breakthrough is demonstrated through its application as a sensitive platform for rapid drug screening, which efficiently validated potential therapeutics like FGF10 eye drops. Furthermore, the study yields its most notable promise in the field of regeneration. Transplanting these human organoids into mice resulted in their successful engraftment, integration with host tissue, and functional oil secretion, providing the first direct proof-of-concept for a future regenerative cell therapy.

While presenting a major advance, the researchers, led by Prof. Zhao, also maintained scientific rigor by transparently characterizing the current limitations of this first-generation model. In-depth analysis revealed a "maturity gap." Single-cell RNA sequencing showed the organoids possess a lower abundance of fully specialized, lipid-producing acinar cells compared to adult glands. Additionally, although the lipid profile is broadly similar, mass spectrometry identified clear and quantifiable differences in lipid composition between the organoids and native tissue.

Proactively addressing these limitations, the team explored strategies for improvement. They discovered that inhibiting the p38 MAPK signaling pathway could effectively drive the organoids toward a more mature state, significantly enhancing their lipid synthesis capability.

This research marks a pivotal shift from managing symptoms to enabling genuine tissue repair. By honestly addressing both the breakthrough and the remaining challenges, and by proposing a clear path forward through mechanisms such as p38 pathway modulation, the work lays a solid and realistic foundation for a future in which personalized organoid testing and functional gland regeneration could become a clinical reality for dry eye patients.
DOI：10.1093/procel/pwaf095